TwinStrand Biosciences announces final judgment in patent infringement suit against Guardant Health, awarding TwinStrand and the University of Washington more than $245.2 million in damages, accrued royalties and interest. August 24, 2026 WOBN news, syndication comments off on TwinStrand Biosciences announces final judgment in patent infringement suit against Guardant Health, awarding TwinStrand and the University of Washington more than $245.2 million in damages, accrued royalties and interest. SEATTLE-(BUSINESS WIRE)-TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing(R) technology, today announced that the U.S. District Court for the District of Delaware entered final judgment on Aug. 21, 2026, in favor of TwinStrand and the University of Washington (UW) in their patent infringement suit against Guardant Health, Inc. (Nasdaq: GH). The final judgment preserves a November 2023 jury verdict finding that Guardant Health willfully infringed two core patents underlying T Click here to view original post

U.S. court orders Guardant to pay $245 million in DNA sequencing patent dispute. By Thomson Reuters Aug 24, 2026 | 7:25 AM Aug 24 (Reuters) - A U.S. court has ordered Guardant Health to pay more than $245.2 million to TwinStrand Biosciences and the University of Washington after finding that the company infringed patents covering DNA sequencing technology, TwinStrand said on Monday. Here are the details: - The U.S. District Court for the District of Delaware entered final judgment on August 21, upholding a 2023 jury verdict that found Guardant had willfully infringed two patents related to TwinStrand's DNA sequencing technology. - The court ordered Guardant to pay a 6% royalty on U.S. sales of 11 products and services found to infringe the patents until they expire in March 2033. - The judgment includes $83.4 million in original damages, $19.5 million in supplemental damages, $119.4 million in accrued royalties, and $22.9 million in pre- and post-judgment interest. - TwinStrand said the products and services covered by the ruling accounted for about 90% of Guardant's revenue during the infringement period. - The products covered by the ruling include Guardant360 CDx, Guardant Reveal, the Shield cancer test and several other cancer testing and genomics services sold by Guardant. - Guardant had sought to overturn the verdict or obtain a new trial, but the court rejected those efforts, TwinStrand said. - The judgment also upheld the validity of the patent claims at issue, TwinStrand said. - TwinStrand's Duplex Sequencing technology is designed to detect rare genetic mutations with greater accuracy than conventional DNA sequencing methods. - TwinStrand said its technology, developed at the University of Washington, is used in cancer research, diagnostics and drug development. (Reporting by Kamal Choudhury in Bengaluru; Editing by Tasim Zahid)

Guardant Health to appeal federal District Court judgment. August 24, 2026 * Current Guardant Reveal, Shield products excluded from final District Court order * Company has validated Guardant360 design improvements to exclude impact of potential royalties PALO ALTO, Calif.-(BUSINESS WIRE)- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. "We strongly disagree with this decision and will promptly be appealing for its overturn," said John Saia, Guardant Health Chief Legal Officer. "We have full faith in the strengths and merits of Guardant's intellectual property and R&D and are confident we will ultimately prevail on appeal." Importantly, the order published on Friday regarding the scope of royalties expressly defined the products included as those that existed at the time of the trial in 2023, many of which have been discontinued or significantly upgraded. Based on Guardant's updated technology the current versions of Guardant Reveal and Shield are excluded from the order and potential royalties. In addition, the company has validated design improvements to Guardant360 and related services that would exclude impact of the potential ongoing royalties in the decision. Guardant remains confident that it did not infringe the asserted patents. Both TwinStrand patents have been preliminarily invalidated in the company's ongoing challenges before the U.S. Patent and Trademark Office. Separately, Guardant is pursuing appeals before the U.S. Court of Appeals for the Federal Circuit. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook. Guardant Health Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.